 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis |
| Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han |
|
Kidney Res Clin Pract. 2017;36(3):274-281. Published online September 30, 2017 DOI: https://doi.org/10.23876/j.krcp.2017.36.3.274 |
|
102 Renoprotective Effects of Febuxostat and Allopurinol in patients with Hyperuricemia and Chronic Kidney Disease: A Meta-Analysis American Journal of Kidney Diseases. 2020;75(4):565  Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis Kidney Research and Clinical Practice. 2017;36(3):274-281 SO012RENOPROTECTIVE EFFECTS OF FEBUXOSTAT AND ALLOPURINOL IN PATIENTS WITH HYPERURICEMIA AND CHRONIC KIDNEY DISEASES: A META-ANALYSIS Nephrology Dialysis Transplantation. 2020;35(Supplement_3): Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout Yearbook of Pediatrics. 2007;2007:501-503 P276 A meta-analysis on the association of febuxostat compared to allopurinol on blood pressure and major adverse cardiac events (MACE) among adult patients with hyperuricemia European Heart Journal. 2020;41(Supplement_1): Comment on: Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis Clinical Cardiology. 2022; Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis Clinical Cardiology. 2021; Reply to comment on “Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta‐analysis” Clinical Cardiology. 2022; Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review Clinical Rheumatology. 2020;39(11):3287-3294 The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia – A systematic review and meta-analysis Nutrition, Metabolism and Cardiovascular Diseases. 2019;29(10):1011-1022 |
